1. Home
  2. PK vs DAWN Comparison

PK vs DAWN Comparison

Compare PK & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Hotels & Resorts Inc.

PK

Park Hotels & Resorts Inc.

HOLD

Current Price

$12.14

Market Cap

2.5B

Sector

Real Estate

ML Signal

HOLD

Logo Day One Biopharmaceuticals Inc.

DAWN

Day One Biopharmaceuticals Inc.

HOLD

Current Price

$21.50

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PK
DAWN
Founded
1946
2018
Country
United States
United States
Employees
90
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.2B
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
PK
DAWN
Price
$12.14
$21.50
Analyst Decision
Hold
Buy
Analyst Count
9
8
Target Price
$11.22
$24.43
AVG Volume (30 Days)
4.2M
2.7M
Earning Date
04-30-2026
05-01-2026
Dividend Yield
8.82%
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$2,791,000,000.00
$158,182,000.00
Revenue This Year
$2.40
$55.03
Revenue Next Year
$2.76
$28.12
P/E Ratio
$244.30
N/A
Revenue Growth
2.35
20.60
52 Week Low
$9.84
$5.64
52 Week High
$12.43
$21.53

Technical Indicators

Market Signals
Indicator
PK
DAWN
Relative Strength Index (RSI) 68.71 80.29
Support Level $10.82 $10.30
Resistance Level $12.36 N/A
Average True Range (ATR) 0.32 0.03
MACD 0.12 -0.28
Stochastic Oscillator 83.19 90.91

Price Performance

Historical Comparison
PK
DAWN

About PK Park Hotels & Resorts Inc.

Park Hotels & Resorts owns upper-upscale and luxury hotels, with 21,042 rooms across 33 hotels in the United States. Park also has interests through joint ventures in another 1,712 rooms in two US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.

About DAWN Day One Biopharmaceuticals Inc.

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.

Share on Social Networks: